轩竹生物-B:安纳拉唑钠III期试验达主要终点,愈合率达88.4%

美股速递
Jun 30

轩竹生物制药股份有限公司宣布,其核心产品安纳拉唑钠的III期临床试验已达到主要疗效终点。数据显示,该药物在治疗相关适应症时,展现出高达88.4%的愈合率,这一积极结果为后续的新药上市申请奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10